[go: up one dir, main page]

PL3373922T3 - Kompozycje i sposoby do stosowania do leczenia homocystynurii - Google Patents

Kompozycje i sposoby do stosowania do leczenia homocystynurii

Info

Publication number
PL3373922T3
PL3373922T3 PL16864878T PL16864878T PL3373922T3 PL 3373922 T3 PL3373922 T3 PL 3373922T3 PL 16864878 T PL16864878 T PL 16864878T PL 16864878 T PL16864878 T PL 16864878T PL 3373922 T3 PL3373922 T3 PL 3373922T3
Authority
PL
Poland
Prior art keywords
homocystinury
compositions
treatment
methods
Prior art date
Application number
PL16864878T
Other languages
English (en)
Inventor
Jan P. Kraus
Tomas Majtan
Erez Bublil
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/935,690 external-priority patent/US9675678B2/en
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of PL3373922T3 publication Critical patent/PL3373922T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16864878T 2015-11-09 2016-11-09 Kompozycje i sposoby do stosowania do leczenia homocystynurii PL3373922T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/935,690 US9675678B2 (en) 2013-01-29 2015-11-09 Compositions and methods for treatment of homocystinuria
EP16864878.0A EP3373922B1 (en) 2015-11-09 2016-11-09 Compositions and methods for use in the treatment of homocystinuria
PCT/US2016/061050 WO2017083327A1 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
PL3373922T3 true PL3373922T3 (pl) 2022-05-02

Family

ID=58696136

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16864878T PL3373922T3 (pl) 2015-11-09 2016-11-09 Kompozycje i sposoby do stosowania do leczenia homocystynurii
PL21204193.3T PL3998067T3 (pl) 2015-11-09 2016-11-09 Kompozycje do leczenia homocystynurii i sposoby jej leczenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21204193.3T PL3998067T3 (pl) 2015-11-09 2016-11-09 Kompozycje do leczenia homocystynurii i sposoby jej leczenia

Country Status (26)

Country Link
US (3) US11077175B2 (pl)
EP (3) EP4487914A3 (pl)
JP (2) JP7009364B2 (pl)
KR (1) KR102819396B1 (pl)
CN (2) CN108472277A (pl)
AU (2) AU2016354030B2 (pl)
BR (1) BR112018007768A2 (pl)
CA (1) CA3001625A1 (pl)
CY (1) CY1125113T1 (pl)
DK (2) DK3998067T3 (pl)
ES (2) ES2909914T3 (pl)
FI (1) FI3998067T3 (pl)
HR (2) HRP20241491T1 (pl)
HU (2) HUE068830T2 (pl)
IL (2) IL258487B2 (pl)
LT (2) LT3373922T (pl)
MX (1) MX2018005312A (pl)
NZ (1) NZ741552A (pl)
PL (2) PL3373922T3 (pl)
PT (2) PT3373922T (pl)
RS (2) RS63070B1 (pl)
SG (1) SG10201912972SA (pl)
SI (2) SI3373922T1 (pl)
SM (2) SMT202400463T1 (pl)
WO (1) WO2017083327A1 (pl)
ZA (1) ZA201802376B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
HRP20241491T1 (hr) 2015-11-09 2025-01-03 The Regents Of The University Of Colorado, A Body Corporate Pripravci i metode za liječenje homocistinurije
JP7146897B2 (ja) 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
EP3990005B1 (en) * 2019-06-26 2025-08-27 Travere Therapeutics Switzerland GmbH Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
WO2021046190A1 (en) * 2019-09-03 2021-03-11 Orphan Technologies Ltd. Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS555429A (en) * 1978-06-23 1980-01-16 Nissan Motor Co Ltd Pressure regulator for fuel injection type gasoline engine
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
WO1996033703A2 (en) 1995-04-25 1996-10-31 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
KR100622796B1 (ko) 1998-04-28 2006-09-13 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 폴리올-ｉｆｎ-베타 공액체
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
CA2377665A1 (en) 1999-07-06 2001-01-11 General Atomics Methods and compositions for assaying analytes
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
US7485307B2 (en) 2002-06-17 2009-02-03 The Regents Of The University Of Colorado Human cystathionine β-synthase variants and methods of production thereof
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) * 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
AU2004288128A1 (en) 2003-07-31 2005-05-19 Anticancer, Inc. The use of PLP with PEG-rMETase in vivo for enhanced efficacy
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
JP6041454B2 (ja) * 2007-03-15 2016-12-07 株式会社 Ｄｎａセキュリティー研究所 Ｄｎａ含有インク組成物
JP5074146B2 (ja) 2007-03-30 2012-11-14 オリンパス株式会社 カプセル型医療装置
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
AU2010286518C1 (en) 2009-08-29 2015-08-27 Abbvie Inc. Therapeutic DLL4 binding proteins
US8709407B2 (en) 2010-02-04 2014-04-29 Aemase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
US9364497B2 (en) 2010-07-01 2016-06-14 Isis Innovation Limited Treatment of cognitive disorders
US9034318B2 (en) * 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) * 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) * 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
JP6987741B2 (ja) 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
HRP20241491T1 (hr) 2015-11-09 2025-01-03 The Regents Of The University Of Colorado, A Body Corporate Pripravci i metode za liječenje homocistinurije
JP7146897B2 (ja) 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
JP7002314B2 (ja) * 2017-12-13 2022-02-10 株式会社ブリヂストン 空気入りタイヤ
EP3990005B1 (en) 2019-06-26 2025-08-27 Travere Therapeutics Switzerland GmbH Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
WO2021046190A1 (en) 2019-09-03 2021-03-11 Orphan Technologies Ltd. Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Also Published As

Publication number Publication date
RS66106B1 (sr) 2024-11-29
KR20180074703A (ko) 2018-07-03
US20220125896A1 (en) 2022-04-28
HUE058749T2 (hu) 2022-09-28
MX2018005312A (es) 2018-08-15
RS63070B1 (sr) 2022-04-29
EP3373922A1 (en) 2018-09-19
DK3998067T3 (da) 2024-10-28
ZA201802376B (en) 2020-11-25
EP4487914A2 (en) 2025-01-08
KR102819396B1 (ko) 2025-06-12
JP2022050589A (ja) 2022-03-30
US20240091325A1 (en) 2024-03-21
US12194082B2 (en) 2025-01-14
HK1258502A1 (en) 2019-11-15
ES2909914T3 (es) 2022-05-10
HRP20241491T1 (hr) 2025-01-03
SI3373922T1 (sl) 2022-05-31
SMT202400463T1 (it) 2025-01-14
CN108472277A (zh) 2018-08-31
AU2022287540A1 (en) 2023-02-02
CN115920016A (zh) 2023-04-07
EP3373922B1 (en) 2022-01-05
SI3998067T1 (sl) 2025-03-31
EP4487914A3 (en) 2025-03-26
IL302198A (en) 2023-06-01
PT3373922T (pt) 2022-03-28
FI3998067T3 (fi) 2024-10-31
LT3998067T (lt) 2024-11-25
US20200276282A1 (en) 2020-09-03
AU2022287540B2 (en) 2025-02-27
ES2994256T3 (en) 2025-01-21
EP3998067A1 (en) 2022-05-18
JP7482914B2 (ja) 2024-05-14
PT3998067T (pt) 2024-11-04
PL3998067T3 (pl) 2025-01-07
AU2016354030A1 (en) 2018-05-10
IL258487A (en) 2018-05-31
EP3998067B1 (en) 2024-09-11
JP2018532763A (ja) 2018-11-08
IL258487B1 (en) 2023-05-01
EP3373922A4 (en) 2019-05-15
AU2016354030B2 (en) 2022-09-15
CY1125113T1 (el) 2024-02-16
US11077175B2 (en) 2021-08-03
JP7009364B2 (ja) 2022-02-10
HRP20220407T1 (hr) 2022-05-27
SMT202200151T1 (it) 2022-05-12
SG10201912972SA (en) 2020-03-30
CA3001625A1 (en) 2017-05-18
IL258487B2 (en) 2023-09-01
LT3373922T (lt) 2022-04-11
WO2017083327A1 (en) 2017-05-18
BR112018007768A2 (pt) 2018-10-23
NZ741552A (en) 2022-04-29
DK3373922T3 (da) 2022-03-28
US11771745B2 (en) 2023-10-03
HUE068830T2 (hu) 2025-01-28

Similar Documents

Publication Publication Date Title
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
PL3265053T3 (pl) Sposoby leczenia skóry
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
IL251904A0 (en) Apilimod for use in the treatment of melanoma
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3302478T3 (da) Pac-1 kombinations behandling
IL257458B1 (en) Dpep-1 binding compositions and methods of use
IL254825A0 (en) Methods of treatment with taselisib